• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is McKesson (MCK) Undervalued As Portfolio Changes And Higher Guidance Refocus Growth?

    Simply Wall St·09/01/2026 22:26:13
    Listen to the news

    Why McKesson Stock Is Back in Focus After Its Latest Moves

    McKesson (MCK) has come back onto investor radars after a series of portfolio changes and a raised fiscal 2027 outlook. The upcoming technology leadership summit appearance adds another angle to how the company frames its future priorities.

    McKesson’s recent portfolio reshaping, including the exit from Canada and Norway and the planned spin-off of its Medical-Surgical unit, has unfolded alongside a strong run in the stock, with a 22.61% 90-day share price return and a 31.62% 1-year total shareholder return that together suggest building momentum rather than fading enthusiasm.

    Spot 50 high quality undervalued stocks that, like McKesson, are reshaping their portfolios and could be positioning for a stronger long term focus on core businesses.

    After a move to about $906 per share and a portfolio that now leans more heavily into U.S. pharmaceuticals and oncology services, does McKesson still offer an attractive trade off between upside potential and execution risk from here?

    Most Popular Narrative: 7.5% Undervalued

    McKesson’s most followed narrative puts fair value at $980.80, above the last close of $906.77, and ties that gap directly to future earnings power and cash returns.

    Increasing adoption of specialty and oncology pharmaceuticals, alongside recent acquisitions (Core Ventures and PRISM Vision) that expand the provider network and service portfolio, are improving revenue mix quality and positioning the company for higher operating margins and earnings growth.

    Read the complete narrative. Read the complete narrative.

    Want to see what underpins that fair value for McKesson? The narrative focuses on specialty growth, small margin gains, and a rerating built around disciplined share count reduction.

    Result: Fair Value of $980.80 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, investors still need to watch policy pressure on drug pricing and the risk of distributors or payers bringing more volume in house, which could challenge McKesson’s thesis.

    Find out about the key risks to this McKesson narrative.

    Next Steps

    With McKesson carrying both clear risks and some appealing rewards, now is the time to look at the numbers yourself and decide how they stack up for your portfolio. To weigh those trade offs side by side, review the 4 key rewards and 1 important warning sign

    Looking for more McKesson style investment ideas?

    If you like how McKesson is sharpening its focus, do not stop here. Use the Simply Wall Street Screener to spot other opportunities before the crowd moves.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.